A Study of Standard of Care Drugs With or Without Ivermectin for Daraxonrasib-Induced Skin Toxicity in People With Pancreatic Cancer

Full Title

A Randomized, Open-Label Study of Standard of Care Prophylaxis versus Standard of Care Prophylaxis Plus Ivermectin for the Prevention of Daraxonrasib-Induced Skin Toxicity in Patients with Metastatic Pancreatic Cancer

Purpose

To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.

Contact

For more information or to see if you can join this study, please call Dr. Allison Gordon’s office at 646-608-2339. 

Protocol
26-384
Phase
Phase II (phase 2)
Investigator
Gordon (Kutner), Allison, MD
Co-Investigators
Alina Markova
Eileen M. O'Reilly
Diseases
Hepatobiliary › Pancreatic Cancer
Locations
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Commack Nonna’s Garden Foundation Center
Memorial Sloan Kettering Basking Ridge
Memorial Sloan Kettering Westchester
Memorial Sloan Kettering Monmouth
Memorial Sloan Kettering Bergen
Memorial Sloan Kettering Nassau
ClinicalTrials.gov ID
NCT07895498
ClinicalTrials.gov
Visit ClinicalTrials.gov for full clinical trial description